ELTX (Elicio Therapeutics) Stock Based Compensation: $3.05 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
32 GF Score
Price $3.11
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Stock Based Compensation?

Elicio Therapeutics ELTX -5.47% 32 Stock Based Compensation is $3.05 Mil as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Elicio Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $0.87 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $3.05 Mil.

Elicio Therapeutics Stock Based Compensation Related Terms

Elicio Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Stock Based Compensation Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial 0.62 0.58 1.18 1.45 2.70

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.71 0.70 0.77 0.87
ELTX
32GF Score
Elicio Therapeutics Inc ELTX
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.05 Mil.

What does a Stock Based Compensation of $3.05 Mil mean?
Elicio Therapeutics (ELTX) has a Stock Based Compensation of $3.05 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Stock Based Compensation too high?
Elicio Therapeutics' current Stock Based Compensation is $3.05 Mil. Overall, Elicio Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Stock Based Compensation compare to GOSS and GANX?
Elicio Therapeutics' Stock Based Compensation of $3.05 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Elicio Therapeutics and its competitors. Elicio Therapeutics's current Stock Based Compensation is $3.05 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Stock Based Compensation of $3.05 Mil. The current Stock Based Compensation is $3.05 Mil. Elicio Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Stock Based Compensation is $3.05 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
32GF Score

Get the complete analysis for ELTX

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.11
Price